The more common and well-defined diseases or syndromes characterized by abnormal movements are discussed here together with the principles of their treatment.
FAMILIAL OR ESSENTIAL TREMOR
A postural tremor may be prominent in otherwise normal subjects. Although the pathophysiologic basis of this disorder is uncertain, it often has a familial basis with an autosomal dominant mode of inheritance. At least four gene loci have been implicated: three using linkage studies—hereditary essential tremor 1 (ETM1), ETM2, ETM3—and one using exome sequencing, ETM4; in some cases (ETM1), the disorder is related to a polymorphism in the D3 dopamine receptor gene (DRD3). There is evidence of involvement of olivocerebellar and cerebello-thalamo-cortical pathways. Decreased levels of GABAA and GABAB receptors have been found postmortem in the dentate nucleus. Patients with essential tremor have a higher risk of developing Parkinson disease than the general population.
Symptoms may develop in the teenage or early adult years but often do not appear until later. The tremor typically involves one or both hands, the head, the voice, or some combination of these, but the legs tend to be spared. Examination usually reveals no other gross abnormalities, but some patients may have mild ataxia or personality disturbances. Although the tremor may increase with time, it often leads to little disability other than cosmetic and social embarrassment. In occasional cases, tremor interferes with the ability to perform fine or delicate tasks with the hands; handwriting is sometimes severely impaired. Speech is affected when the laryngeal muscles are involved. A small quantity of alcohol sometimes provides remarkable but transient relief; the mechanism is not known. The diagnosis is made on clinical grounds by the type of tremor and absence of other causes of tremor or neurologic abnormalities.
If treatment is warranted to reduce tremor amplitude, propranolol, 40 to 160 mg orally twice daily, can be prescribed but will need to be taken indefinitely. Other beta-blockers, such as atenolol and sotalol, have also been used. If tremor is particularly disabling under certain predictable circumstances, a single oral dose of 40 to 120 mg of propranolol can be taken in anticipation of the precipitating circumstances.
Primidone is also effective, but patients are often particularly sensitive to it; it is therefore introduced more gradually than when used for epilepsy. Patients are started on 50 mg/d, and the daily dose is increased by 50 mg every 2 weeks until benefit occurs or side effects limit further increments. A dose of 100 or 150 mg three times a day is often effective. There is no evidence that high doses (exceeding 750 mg daily) provide any added benefit.
Occasional patients respond to alprazolam, up to 3 mg/d in divided doses. Some patients reportedly benefit from gabapentin (1,200 mg/d), topiramate (400 mg/d), zonisamide (up to 200 mg daily), or intramuscular injections of botulinum toxin. When tremor is disabling and unresponsive to pharmacologic measures, surgical measures may be necessary. High-frequency thalamic stimulation by an implanted electrode is effective and has a low morbidity. Benefit is maintained over the years in most patients with severe disability. Thalamotomy may be helpful but has a significantly higher morbidity than thalamic stimulation.
R. Treatment of patients with essential tremor. Lancet Neurol. 2011;10:148–161.
ED. Essential tremor: from bedside to bench and back to bedside. Curr Opin Neurol. 2014;27:461–467.
GA. Genetics of essential tremor: from phenotype to genes, insights from both human and mouse studies. Prog Neurobiol. 2014;119-120:1–19.
Parkinsonism occurs in all ethnic groups; in the United States and Western Europe it has a prevalence of 1 to 2 per 1,000 population, with an approximately equal sex distribution. The disorder becomes increasingly common with advancing age. It is characterized by tremor, hypokinesia, rigidity, and abnormal gait and posture.
The most common variety of parkinsonism occurs without obvious cause; this idiopathic form is called Parkinson disease or paralysis agitans when there are no atypical features, it is not secondary to some known cause, and there is a sustained response to treatment with dopaminergic medication. During a preclinical phase extending back for several years before the development of the motor deficit, hyposmia, constipation, anxiety, depression, and rapid-eye-movement (REM) sleep behavior disorder may be present.
In the first half of the 20th century, parkinsonism often developed in patients with a history of von Economo encephalitis lethargica, but such cases of postencephalitic parkinsonism are becoming rare, although parkinsonism still occasionally follows other encephalitic illnesses.
Drug- or Toxin-Induced Parkinsonism
Therapeutic drugs—Many drugs, such as phenothiazines, butyrophenones, metoclopramide, reserpine, and tetrabenazine, can cause a reversible parkinsonian syndrome (see later). This is usually reversible by withdrawing the offending medication, although symptoms and signs may take many months to resolve.
Toxic substances—Environmental toxins such as manganese dust or carbon disulfide can lead to parkinsonism; manganese used in the home manufacture of methcathinone appears to have been responsible for parkinsonism in intravenous users of this illegal stimulant. The disorder may also appear as a sequela of severe carbon monoxide poisoning and rarely after exposure to pesticides or fumes during welding.
MPTP (1-methyl-4-phenyl-1,2,5,6-tetrahydropyri-dine)—A drug-induced form of parkinsonism occurred in individuals who synthesized and self-administered a meperidine analogue, MPTP. This compound is metabolized to a toxin that selectively destroys dopaminergic neurons in the substantia nigra and adrenergic neurons in the locus ceruleus and induces a severe form of parkinsonism in humans and nonhuman primates. The ability of this drug to reproduce neurochemical, pathologic, and clinical features of Parkinson disease suggests that an environmental toxin could be responsible for the idiopathic disorder. MPTP-induced parkinsonism has been used as a model to assist in the development of new drugs for treatment of this disease.
Multiple subcortical white-matter infarcts may lead to symptoms and signs suggestive of parkinsonism, usually accompanied by brisk tendon reflexes and extensor plantar responses. Tremor is often relatively inconspicuous and, in some patients, abnormalities of gait are especially evident (“lower-body parkinsonism”). The MRI findings help to suggest or support the diagnosis, and management is focused on preventing stroke. The response to antiparkinsonian medication is usually disappointing.
Boxers and those in certain other contact sports, such as football, may develop a syndrome of dementia (dementia pugilistica), behavioral and psychiatric disturbances, parkinsonism, and pyramidal and cerebellar deficits from recurrent head trauma leading to a chronic traumatic encephalopathy. There is no satisfactory treatment.
Familial & Genetic Parkinsonism
Rarely, parkinsonism occurs on a familial basis. Autosomal dominant parkinsonism may result from mutations of one of several genes, including α-synuclein (SNCA), leucine-rich repeat kinase 2 (LRRK2), and ubiquitin carboxylterminal esterase L1 (UCHL1) (Table 11-6). Mutations in parkin (PARK2) and DJ1 cause early onset, autosomal recessive, and sporadic juvenile-onset parkinsonism. Several other genes or chromosomal regions have been implicated in familial forms of the disease or as susceptibility factors, including the gene for beta glucosidase (GBA), the enzyme deficient in the lysosomal storage disorder Gaucher disease.
Table 11-6.Genes Implicated in Hereditary Parkinsonism. |Favorite Table|Download (.pdf) Table 11-6. Genes Implicated in Hereditary Parkinsonism.
|Designation ||Gene ||Protein ||Inheritance ||Age at Onset ||Additional Clinical Features or Comments |
|PARK1 ||SNCA ||α-Synuclein ||AD ||40s ||May be rapidly progressive; dementia may occur |
|PARK2 ||PARK2 ||Parkin ||AR ||< 40 ||Onset is older with mutation in only 1 allele; may be dystonic features and hyperreflexia. Sensory axonal neuropathy sometimes found |
|PARK3 ||Unknown ||Unknown ||AD ||Variable ||Mutation may affect age of onset |
|PARK4 ||SNCA (triplication) ||α-Synuclein ||AD ||∼ 45 ||Early weight loss. Rapidly progressive. Dementia and dysautonomia may occur |
|PARK5 ||UCHL1 ||Ubiquitin carboxyl-terminal esterase L1 ||AD ||? ||Few cases reported |
|PARK6 ||PINK1 ||PTEN-induced putative kinase 1 ||AR ||∼ 40 ||Indistinguishable for classic Parkinson disease. Some resemble PARK2 |
|PARK7 ||DJ1 ||DJ1 ||AR ||∼ 40 ||Slow progression. Blepharospasm may occur |
|PARK8 ||LRRK2 ||Leucine-rich repeat kinase 2 (dardarin) ||AD ||50-70 ||Indistinguishable for classic Parkinson disease. Slow progression. Dementia rare |
|PARK9 ||ATP13A2 ||ATPase type 13A2 ||AR ||< 40 ||Hyperreflexia, dementia, supranuclear palsy, visual hallucinations may occur. Initially good but short-lived response to levodopa |
|PARK11 ||GIGYF2 ||GRB-interacting GYF protein 2 ||AD || ||Evidence is inconsistent that variation in the GIGYF2 gene relates to parkinsonism |
|PARK13 ||HTRA2 ||HTRA serine peptidase 2 ||AD ||Late onset ||Limited information available |
|PARK14 ||PLA2G6 ||Phospholipase A2, group VI ||AR ||< 40 ||Parkinsonism, dystonia, hyperreflexia, dementia, cortical atrophy, rapidly progression, sometimes with brain iron accumulation |
|PARK15 ||FBXO7 ||F-box only protein 7 ||AR ||< 30 ||Parkinsonism and pyramidal signs |
|PARK 17 ||VPS35 ||Vacuolar protein sorting-associated protein 35 ||AD ||40-60 ||Similar to classic Parkinson disease |
|PARK18 ||EIF4G1 ||Eukaryotic translation initiation factor 4 gamma 1 ||AD ||50-80 ||Similar to classic Parkinson disease |
|PARK19 ||DNAJC6 ||Putative tyrosine-protein phosphatase auxilin ||AR ||< 20 ||Dystonia and pyramidal signs may be present |
|PARK 20 ||SYNJ1 ||Synaptojanin 1 ||AR ||20s ||May be accompanied by dystonia, seizures cognitive decline, abnormal eye movements |
Parkinsonism Associated With Other Neurologic Diseases
Parkinsonism that occurs in association with symptoms and signs of other neurologic disorders is considered briefly in the later section on differential diagnosis.
Idiopathic parkinsonism (Parkinson disease) is a proteinopathy characterized by the misfolding and aggregation of α-synuclein. It is thus also referred to as a synucleinopathy. Histopathologic examination at advanced stages shows loss of pigmentation and cells in the substantia nigra and other brainstem centers, cell loss in the globus pallidus and putamen, and filamentous eosinophilic intraneural inclusion granules (Lewy bodies) containing α-synuclein in the basal ganglia, brainstem, spinal cord, and sympathetic ganglia. The distribution of Lewy bodies is more widespread than originally appreciated, with early involvement of the lower brainstem (eg, dorsal motor nucleus of the vagus [X] nerve), olfactory bulb, and enteric nervous system, and subsequent spread to the locus ceruleus, substantia nigra, transentorhinal cortex, hippocampus, and neocortex. Lewy bodies are not seen in postencephalitic parkinsonism; instead there may be nonspecific neurofibrillary degeneration in a number of diencephalic structures as well as changes in the substantia nigra.
As in other neurodegenerative proteinopathies (discussed in Chapter 5, Dementia & Amnestic Disorders), the disease is thought to be triggered by protein misfolding and aggregation—in Parkinson disease, the protein involved is α-synuclein. Abnormal protein may subsequently spread from cell to cell and thereby propagate the disease to contiguous parts of the nervous system.
The motor manifestations of Parkinson disease appear to result from altered patterns of inhibition and excitation within the basal ganglia and its connections via direct and indirect pathways (Figure 11-2). Dopamine and acetylcholine act as neurotransmitters in this region. In idiopathic parkinsonism, the normal balance between these two antagonistic neurotransmitters is disturbed because of dopamine depletion in the dopaminergic nigrostriatal system (Figure 11-3). Other neurotransmitters, such as norepinephrine, are also depleted in the brains of patients with parkinsonism, but the clinical relevance of this deficiency is less clear.
Functional circuitry between the cerebral cortex, basal ganglia, and thalamus. The major neurotransmitters and their excitatory (+) or inhibitory (−) effects are indicated. In Parkinson disease, there is degeneration of the pars compacta of the substantia nigra, leading to overactivity in the indirect pathway (red) and increased glutamatergic output from the subthalamic nucleus. (Used with permission from Aminoff MJ. Pharmacologic management of parkinsonism and other movement disorders. In: Katzung BG, Masters SB, Trevor AJ, eds. Basic and Clinical Pharmacology. 11th ed. New York, NY: McGraw-Hill; 2009.)
Schematic representation of the sequence of neurons involved in parkinsonism. Top: Dopaminergic neurons (red) originating in the substantia nigra normally inhibit the GABAergic output from the striatum (caudate and putamen), whereas cholinergic neurons (green) exert an excitatory effect. Bottom: In parkinsonism, there is a selective loss of dopaminergic neurons (dashed, red). This leads to increased inhibitory output from the striatum. (Used with permission from Aminoff MJ. Pharmacologic management of parkinsonism and other movement disorders. In: Katzung BG, Masters SB, Trevor AJ, eds. Basic and Clinical Pharmacology. 12th ed. New York, NY: McGraw-Hill; 2012.)
The 4- to 6-Hz tremor of parkinsonism is characteristically most conspicuous at rest; it increases at times of emotional stress and often improves during voluntary activity. It commonly begins with rhythmic, opposing circular movements of the thumb and index finger (“pill-rolling”), as rhythmic flexion–extension of the fingers or of the hand or foot—or rhythmic pronation–supination of the forearm. It frequently involves the lower jaw and chin as well. Although it may ultimately be present in all limbs, it is not uncommon for the tremor to be confined to one limb—or both limbs on one side—for months or years before it becomes more generalized. In some patients, tremor never becomes prominent.
Rigidity or increased tone (ie, increased resistance to passive movement) is characteristic of parkinsonism. The disturbance in tone is responsible for the flexed posture of many patients. The resistance is typically uniform throughout the range of movement at a particular joint and affects agonist and antagonist muscles alike—in contrast to spasticity, where it is often greatest at the beginning of the passive movement (clasp-knife phenomenon) and more marked in some muscles than others. In some instances, the rigidity in parkinsonism is described as cogwheel rigidity because of ratchet-like interruptions of passive movement that may be due, in part, to the presence of tremor.
The most disabling feature of parkinsonism is hypokinesia (sometimes called bradykinesia or akinesia)—a slowness of voluntary movement and a reduction in automatic movement, such as swinging the arms while walking. The patient’s face is relatively immobile (hypomimia or masklike facies), with widened palpebral fissures, infrequent blinking, a certain fixity of facial expression, and a smile that develops and fades slowly. The voice is soft (hypophonia) and poorly modulated. Fine or rapidly alternating movements are impaired, but power is not diminished if time is allowed for it to develop. The handwriting is small (micrographia), tremulous, and hard to read.
The patient finds it difficult to get up from bed or an easy chair and adopts a flexed posture on standing (Figure 11-4). It is often difficult to start walking, so the patient may lean farther and farther forward while walking in place before being able to advance. The gait itself is characterized by small, shuffling steps and absence of the arm swing that normally accompanies locomotion; there is generally some unsteadiness on turning, and there may be difficulty in stopping. Retained arm swing, wide-based gait, or marked imbalance at an early stage suggests a nonparkinsonian disorder. In advanced cases, the patient tends to walk with increasing speed to prevent a fall (festinating gait) because of the altered center of gravity that results from the abnormal posture.
Typical flexed posture of a patient with parkinsonism.
Other Motor Abnormalities
There is often mild blepharoclonus (fluttering of the closed eyelids) and occasionally blepharospasm (involuntary closure of the eyelids). The patient may drool, perhaps because of impairment of swallowing. There is typically no alteration in the tendon reflexes (although a mild hyperreflexia may occur on the affected side in asymmetric parkinsonism), and the plantar responses are flexor. Repetitive tapping (approximately twice per second) over the bridge of the nose produces a sustained blink response (Myerson sign); the response is not sustained in normal subjects.
Anosmia is an early symptom (but may arise from many other causes, and is therefore not a specific indicator of Parkinson disease). Cognitive decline, executive dysfunction, and personality changes are common, as are depression and anxiety. Apathy may be conspicuous. A sense of fatigue may be prominent, and some patients complain of pain or sensory disturbances. Dysautonomic symptoms include urinary urgency and urge incontinence, and constipation; postural hypotension relates most commonly to dopaminergic therapy or inactivity but may also reflect baroreflex failure or denervation of cardiac muscle. Sleep disorders including REM behavior disorder are common. Seborrheic dermatitis may occur.
The diagnosis may be difficult to make in mild cases. Some degree of slowing is normal in the elderly, and certain otherwise normal people have a deliberate slowness about them.
Depression may be accompanied by a somewhat expressionless face, poorly modulated voice, and reduction in voluntary activity; it can thus simulate parkinsonism. Moreover, the two diseases often coexist. A trial of antidepressant drug treatment may be helpful in some instances.
Essential (Benign Familial) Tremor
This was considered separately (see earlier). An early age at onset, a family history of tremor, the relationship of the tremor to activity, a beneficial effect of alcohol on the tremor, and a lack of other neurologic signs distinguish this disorder from parkinsonism. Furthermore, essential tremor commonly affects the head (causing a nod or head shake); parkinsonism typically affects the lower jaw and chin.
This group of disorders is characterized by parkinsonism plus clinical evidence of more widespread disease from degeneration in other neuronal systems. Depending on the disorder, they are either synucleinopathies or tauopathies. They typically respond poorly to dopaminergic medication and have a poorer prognosis than Parkinson disease. These disorders include diffuse Lewy body disease, multisystem atrophy, progressive supranuclear palsy, and corticobasal degeneration, which are all discussed later in this chapter.
A dystonic tremor may also be mistaken for parkinsonism, particularly when the dystonia is mild or unrecognized.
Wilson disease (discussed later) can lead to a parkinsonian syndrome, but other varieties of abnormal movements are usually present as well. Moreover, the early age at onset and the presence of Kayser-Fleischer rings should distinguish Wilson disease from Parkinson disease, as should abnormalities in serum and urinary copper and serum ceruloplasmin.
Huntington disease may occasionally be mistaken for parkinsonism when it presents with rigidity and akinesia, but a family history of Huntington disease or an accompanying dementia, if present, should suggest the correct diagnosis, which can be confirmed by genetic studies.
This prion disease may be accompanied by parkinsonian features, but dementia is usually present, myoclonic jerks are common, and ataxia is sometimes prominent; there may be pyramidal or cerebellar signs and visual disturbances, and the EEG findings of periodic discharges are usually characteristic.
Normal Pressure Hydrocephalus
This condition leads to a gait disturbance (often mistakenly attributed to parkinsonism), urinary incontinence, and dementia. CT scanning reveals dilation of the ventricular system of the brain without cortical atrophy. The disorder may follow head injury, intracranial hemorrhage, or meningoencephalitis, but the cause is often obscure. Surgical shunting procedures to bypass any obstruction to the flow of cerebrospinal fluid (CSF) are often beneficial. Normal pressure hydrocephalus is discussed in more detail in Chapter 5, Dementia & Amnestic Disorders.
Early parkinsonism requires no drug treatment, but it is important to discuss with the patient the nature of the disorder and the availability of medical treatment if symptoms become more severe, and to encourage activity. Treatment of the motor symptoms, when indicated, is directed toward restoring the dopaminergic–cholinergic balance in the striatum by blocking the effect of acetylcholine with anticholinergic drugs or by enhancing dopaminergic transmission (Figure 11-5).
Pharmacologic basis of antiparkinsonian dopaminergic therapy. (Used with permission from Aminoff MJ. Pharmacologic management of parkinsonism and other movement disorders. In: Katzung BG, Masters SB, Trevor AJ, eds. Basic and Clinical Pharmacology. 12th ed. New York, NY: McGraw-Hill; 2012.)
Muscarinic anticholinergic drugs are more helpful in alleviating tremor and rigidity than hypokinesia but are generally less effective than dopaminergic drugs (see later). A number of preparations are available, and individual patients tend to favor different drugs. Among the most commonly prescribed drugs are trihexyphenidyl and benztropine (Table 11-7). Treatment is started with a small dose of one of the anticholinergics; the dosage is then gradually increased until benefit occurs or side effects limit further increments. If treatment is not helpful, the drug is withdrawn and another anticholinergic preparation is tried. Anticholinergic drugs are best avoided in the elderly because of their side effects, which include dry mouth, constipation, urinary retention, defective pupillary accommodation, and confusion.
Table 11-7.Drugs Used in the Treatment of Parkinson Disease. |Favorite Table|Download (.pdf) Table 11-7. Drugs Used in the Treatment of Parkinson Disease.
|Drug ||Total Daily Dose (mg)1 |
|Amantadine (Symmetrel) ||100-300 |
|Levodopa (Sinemet; Stalevo; Parcopa) ||300-1,0002 |
Amantadine can be given for mild parkinsonism either alone or in combination with an anticholinergic agent. Its precise mode of therapeutic action is unclear, but its pharmacologic effects include blockade of NMDA-preferring glutamate and muscarinic cholinergic receptors and stimulation of dopamine release. Amantadine improves all the motor features of parkinsonism, its side effects (restlessness, confusion, skin rashes, edema, disturbances of cardiac rhythm) are relatively uncommon, its effects are exerted rapidly, and it is given in a standard dose of 100 mg orally twice daily. Unfortunately, however, many patients fail to respond to this drug, or its benefit is short-lived. Amantadine may also be useful in reducing the sense of extreme fatigue experienced by some patients and for iatrogenic dyskinesias in patients with advanced disease (100 mg two or three times daily).
Levodopa, which is converted in the body to dopamine (see Figure 11-5), ameliorates all the major clinical features of parkinsonism and, unlike the anticholinergic drugs, is often particularly helpful against hypokinesia. Carbidopa is a drug that reduces the extracerebral metabolism of levodopa to dopamine by inhibiting dopa decarboxylase (see Figure 11-5), but it does not cross the blood–brain barrier. Accordingly, when levodopa is given with carbidopa, the breakdown of levodopa is limited outside the brain. Carbidopa is generally combined with levodopa in a fixed proportion (1:10 or 1:4) as carbidopa/levodopa. There remains disagreement about the best time to introduce it. Concerns that levodopa may lose its effectiveness with time (as opposed to with advance of the disease) are misplaced, but response fluctuations sometimes occur after it has been used for several years, and may be particularly disabling. These may relate to the disease itself or to the duration of levodopa treatment. Many physicians therefore defer the introduction of levodopa for as long as possible or use dopamine agonists (discussed later) in conjunction with it to keep the levodopa dose low.
Treatment is started with a small dose, such as carbidopa/levodopa 10/100 mg or 25/100 mg orally three times daily, and the dose is gradually increased, depending on the response. Many patients ultimately require carbidopa/levodopa 25/250 (mg) three or four times daily. Carbidopa should total at least 75 mg/d. The medication is best taken about 30 to 45 minutes before meals or 2 hours after meals to maximize absorption and uptake into the brain. A tablet of carbidopa/levodopa (25/100, 10/100, 25/250) that disintegrates in the mouth and is then swallowed with the saliva (Parcopa) is also available and is best taken about 1 hour before meals.
The most common side effects of levodopa are nausea, vomiting, hypotension, abnormal movements (dyskinesias), restlessness, and confusion. Cardiac arrhythmias occur occasionally. The incidence of nausea, vomiting, hypotension, and cardiac irregularities is reduced when levodopa is taken with carbidopa. The late dyskinesias and behavioral side effects of levodopa occur as dose-related phenomena, but reduction in dose may diminish any therapeutic benefit. Treatment with olanzapine, quetiapine, or risperidone may relieve confusion and psychotic mental disturbances without blocking the effects of levodopa or exacerbating parkinsonism. Clozapine, a dibenzodiazepine derivative that does not block the therapeutic effects of dopaminergic medication, may also relieve confusion and psychotic mental disturbances and, in some instances, the dyskinesias, but requires regular monitoring of the leukocyte count.
Another late complication of levodopa therapy or consequence of advancing disease is response fluctuation such as the wearing-off effect, in which deterioration occurs shortly before the next dose is to be taken, or the on–off phenomenon, in which abrupt but transient fluctuations in the severity of parkinsonism occur at frequent intervals during the day, apparently without any relationship to the last dose of levodopa. Such fluctuations may be disabling and may relate to discontinuous (pulsatile) levels of cerebral dopamine. They can be controlled only partly by varying the dosing intervals; restricting dietary protein intake; use of a controlled-release preparation of carbidopa/levodopa; addition of entacapone, selective monoamine oxidase type B inhibitors, or dopamine agonists to the medication regimen; or administration of carbidopa/levodopa via portable intraduodenal pump. They often respond well to deep brain stimulation.
Levodopa therapy (either alone or in conjunction with carbidopa) is contraindicated in patients with narrow-angle glaucoma or psychotic illness and should be avoided in patients receiving monoamine oxidase type A (MAO-A) inhibitors. It should also be used with care in patients with active peptic ulcers or suspected malignant melanomas.
The older agonists are ergot derivatives such as bromocriptine, which stimulates dopamine D2 receptors. It is perhaps slightly less effective than levodopa in relieving the symptoms of parkinsonism but is less likely to cause dyskinesias. Bromocriptine is now used infrequently, as more effective dopamine agonists are available.
Pergolide is another ergot derivative and dopamine receptor agonist; unlike bromocriptine, it activates both D1 and D2 receptors. Its indications, side effects, and contraindications are similar to those of bromocriptine, and it is unclear whether either compound is clinically superior to the other. Pergolide was used for many years but has been associated with the development of valvular heart disease in approximately one-third of patients and has therefore been withdrawn by the manufacturer.
The newer dopamine agonists are not ergot derivatives. They seem to be as effective as the older agonists but are without their potential ergot-related adverse effects and may be used in early or advanced Parkinson disease. Pramipexole is started at 0.125 mg three times daily; the daily dose is doubled after 1 week and again after another week; it is then increased by 0.75 mg each week according to response and tolerance. A common maintenance dose is between 0.5 and 1.5 mg three times daily. Ropinirole is started at 0.25 mg three times daily, and the total daily dose increased at weekly intervals by 0.75 mg until the fourth week and by 1.5 mg thereafter. Most patients need between 2 and 8 mg three times daily for benefit. Adverse effects of these medications include fatigue, somnolence, nausea, peripheral edema, dyskinesias, confusion, hallucinations, and orthostatic hypotension. An irresistible urge to sleep at inappropriate times sometimes occurs and may lead to injury. Disturbances of impulse control may lead to such behaviors as compulsive gambling or abnormal sexual activity. Extended-release preparations of both pramipexole and ropinirole are available.
Apomorphine hydrochloride, a nonselective dopamine receptor agonist administered by subcutaneous injection, may help rescue patients with advanced parkinsonism and severe “off” episodes of akinesia despite optimized oral therapy. Side effects include severe nausea and vomiting, somnolence, hallucinations, chest pain, and hyperhidrosis; dyskinesias may be enhanced. It should not be prescribed by physicians who are unfamiliar with its potential complications and interactions.
Catechol-O-methyltransferase (COMT) is one of two principal enzymes involved in the metabolic breakdown of dopamine (see Figure 11-5); the other is monoamine oxidase, discussed later. COMT inhibitors may be used to reduce the dose requirements of and any response fluctuations to levodopa. Their use leads to more sustained plasma levels of levodopa, with improved transport into the blood and across the blood–brain barrier. Side effects include diarrhea, confusion, dyskinesias, and abnormalities of liver function tests. Two of these inhibitors are in widespread use. Tolcapone is taken in a daily dose of 100 or 200 mg three times daily. Acute hepatic necrosis has occurred in rare instances in patients receiving this medication and, accordingly, entacapone (200 mg) taken with carbidopa/levodopa up to five times daily is generally preferred.
A commercial preparation named Stalevo is now available that combines levodopa with both carbidopa and entacapone. It provides the convenience of simplifying the drug regime and requiring the consumption of fewer tablets, and is available in three combinations: Stalevo 50 (50 mg levodopa plus 12.5 mg carbidopa and 200 mg entacapone), Stalevo 100 (100 mg, 25 mg, and 200 mg, respectively), and Stalevo 150 (150 mg, 37.5 mg, and 200 mg, respectively). More sustained plasma levels of levodopa may lead to more continuous delivery of levodopa to the brain, with a consequent reduction in the risk of response fluctuations and dyskinetic complications. However, initiating levodopa therapy with Stalevo rather than carbidopa/levodopa fails to delay the time of onset or reduce the frequency of dyskinesia; indeed, dyskinesias may occur sooner and with increased frequency.
Monoamine Oxidase Inhibitors
Selegiline, an irreversible monoamine oxidase type B (MAO-B) inhibitor, inhibits the metabolic breakdown of dopamine (see Figure 11-5). It thus enhances the antiparkinsonian effect of levodopa and may reduce mild on–off fluctuations in responsiveness. Some clinical studies suggest that selegiline may also delay the progression of Parkinson disease, although the evidence is incomplete in this regard; when used for neuroprotection, selegiline is best kept for patients with mild disease. The dose is 5 mg orally twice daily, usually given early in the day to avoid insomnia.
Rasagiline is a more potent and selective, well-tolerated, irreversible MAO-B inhibitor that is taken in a dose of 0.5 or 1 mg once daily. It is effective in the initial treatment of early parkinsonism and in addition as adjunctive therapy in patients with more advanced disease and response fluctuations to levodopa. It may also slow disease progression, although the evidence for this is ambiguous.
Surgical treatment of parkinsonism by thalamotomy or pallidotomy was often undertaken when patients became unresponsive to pharmacologic measures or developed intolerable adverse reactions to antiparkinsonian medication. The rate of significant complications was less than 5% after unilateral pallidotomy or thalamotomy, but approximately 20% or more after bilateral procedures. Ablative surgery has now largely been replaced by high-frequency stimulation of target structures, with a significant reduction in morbidity.
High-frequency stimulation of the globus pallidus or subthalamic nucleus may help all the cardinal motor features of parkinsonism to a similar degree as ablative surgery, and reduces the time spent in the off-state in patients with response fluctuations. Gait disturbances and akinesia may be helped by stimulation of the pedunculopontine nucleus. Deep brain stimulation has the advantage of being reversible, of having a much lower morbidity than ablative surgical procedures (especially when bilateral procedures are contemplated), and of causing minimal damage to the brain. It is thus preferred over ablative procedures. Candidates should have classic Parkinson disease (rather than atypical parkinsonism), be cognitively intact and cooperative, have previously responded well to pharmacologic treatment, have developed response fluctuations with a significant amount of off-time, and have realistic expectations of the procedure.
Autologous or fetal adrenal medullary tissue or fetal substantia nigra has been transplanted to the putamen or caudate nucleus in the belief that the transplanted tissue would continue to synthesize and release dopamine. In two controlled trials involving intracerebral transplantation of human embryonic mesencephalic tissue containing dopaminergic neurons, dyskinetic complications occurred and were sometimes incapacitating. Moreover, Lewy body pathology sometimes spread to the transplanted tissue. Research is currently focused on potential cellular therapies involving neural stem cells, but much work needs to be done before clinical trials can commence in Parkinson disease.
Attempts have been made to slow the progression of Parkinson disease by influencing the mechanisms involved in cell death. In addition to treatment with monoamine oxidase inhibitors such as selegiline or rasagiline (which also have antiapoptotic properties), candidate therapies include those that enhance mitochondrial function or cell energetics, limit glutamate toxicity, inhibit inflammatory responses, or have antiapoptotic effects. However, the results of clinical trials have been disappointing.
General Measures, Physical Therapy, & Aids for Daily Living
Cognitive abnormalities and psychiatric symptoms may be helped by rivastigmine (3-12 mg daily), donepezil (5-10 mg daily), or memantine (5-10 mg daily); psychosis or hallucinations by adjustment of dopaminergic regimen or addition of atypical antipsychotics (eg, quetiapine); excessive daytime sleepiness by modafinil (100-400 mg daily); REM sleep behavior disorder by clonazepam (0.5-2 mg at night); and a hyperactive bladder by oxybutynin (5-15 mg daily) or tolterodine (2-4 mg daily). Constipation may respond to stool softeners or osmotic laxatives and fatigue to amantadine. Physical therapy and speech therapy (Lee Silverman technique) are beneficial to many patients, and the quality of life can often be improved with simple aids to daily living. Such aids may include extra rails or banisters placed strategically about the home for additional support, table cutlery with large handles, nonslip rubber table mats, devices to amplify the voice, and chairs that gently eject the occupant at the push of a button.
K. Clinical outcome of deep brain stimulation for Parkinson’s disease. Handb Clin Neurol. 2013; 116:107–128.
MJ. Therapies for dopaminergic-induced dyskinesias in Parkinson disease. Ann Neurol. 2011; 69:919–927.
et al.. Practice parameter: treatment of nonmotor symptoms of Parkinson disease: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2010;74:924–931.
Up to 15% of all patients with dementia have diffuse Lewy body disease (also discussed in Chapter 5, Dementia & Amnestic Disorders), which typically has its age of onset between 50 and 85 years. Cognitive changes leading to dementia are conspicuous and usually precede or occur shortly after the appearance of parkinsonian deficits. Cognitive function may fluctuate markedly over the 24-hour period. Visual hallucinations are common but may not be distressing. Many patients have unexplained periods of markedly increased confusion or delirium. Parkinsonian deficits become increasingly severe with time, but tremor is often relatively inconspicuous compared with bradykinesia and rigidity. Postural hypotension and syncope are common. The disorder is characterized pathologically by the occurrence of Lewy bodies diffusely in cortical and subcortical structures. In some instances, mutations in the α-synuclein or β-synuclein genes have been described; mutations in other genes may also be implicated.
Parkinson disease differs in that cognitive function is preserved until a later stage, and motor involvement is more likely to be asymmetric in onset, with more conspicuous tremor. The marked variability over short periods of time and the accompanying motor deficit differentiate Lewy body disease from Alzheimer disease. Imaging in Lewy body disease reveals generalized cortical atrophy.
Management of Lewy body disease is difficult because levodopa induces hallucinations and exacerbates the cognitive and behavioral disturbances while providing only limited benefit to the motor disturbance. Anticholinergic drugs are best avoided because they also may exacerbate cognitive dysfunction. The dementia and behavioral abnormalities often respond favorably to cholinesterase inhibitors. Antipsychotic medication is usually poorly tolerated; if necessary, however, low doses of atypical antipsychotics, such as quetiapine (up to 50 mg daily) can be prescribed. Education and support of caregivers are important.
JR. Dementia with Lewy bodies. Semin Neurol. 2013;33:330–335.
Multiple system atrophy (MSA) is a progressive neurodegenerative disorder (a synucleinopathy) with multisystem motor abnormalities and often a dysautonomia. It is more common in men and occurs usually in the sixth decade. One subtype of MSA, referred to as MSA-P, is associated with neuronal loss in the putamen, globus pallidus, and caudate nucleus and presents with bradykinesia and rigidity. Anterocollis is often especially conspicuous. Another type (MSA-C) is associated with cerebellar degeneration (see Chapter 8, Disorders of Equilibrium). When autonomic insufficiency is a conspicuous accompaniment, the eponymous designation of Shy-Drager syndrome is sometimes used. This latter syndrome is characterized by parkinsonian features, autonomic insufficiency (leading to postural hypotension, anhidrosis, disturbance of sphincter control, and impotence), and signs of more widespread neurologic involvement (pyramidal or lower motor neuron signs and often a cerebellar deficit). MRI reveals a hypointense putamen with a hyperintense rim.
The autonomic and multisystem—often symmetric—motor findings with marked anterocollis distinguish the disorder from classic Parkinson disease.
There is no treatment for the motor deficit (although a modest response to antiparkinsonian agents occurs occasionally), but postural hypotension may respond to a liberal salt diet, fludrocortisone 0.1 to 0.5 mg/d, midodrine (an α-adrenergic receptor agonist) 10 mg three times daily, wearing waist-high elastic hosiery, and sleeping with the head up at night.
The disease follows a progressive course leading to death over about 8 to 10 years.
EE. The clinical approach to autonomic failure in neurological disorders. Nat Rev Neurol. 2014;10:396–407.
W. Multiple system atrophy. Lancet Neurol. 2004;3:93–103.
PROGRESSIVE SUPRANUCLEAR PALSY
Progressive supranuclear palsy is an idiopathic, usually sporadic, degenerative disorder, a tauopathy (see Chapter 5, Dementia & Amnestic Disorders) that primarily affects subcortical gray matter regions of the brain. There is much overlap clinically and pathologically with corticobasal degeneration (discussed later). The principal neuropathologic finding is neuronal degeneration with the presence of neurofibrillary tangles in the midbrain, pons, basal ganglia, and dentate nuclei of the cerebellum. Associated neurochemical abnormalities include decreased concentrations of dopamine and its metabolite homovanillic acid in the caudate nucleus and putamen. Pathogenesis seems to relate to both a genetic predisposition and mitochondrial dysfunction.
Men are affected twice as often as women, and the disorder has its onset between ages 45 and 75 years. The classic clinical features are gait disturbance with early falls, supranuclear ophthalmoplegia, pseudobulbar palsy, axial dystonia with or without extrapyramidal rigidity of the limbs, and dementia.
Supranuclear ophthalmoplegia is characterized by prominent failure of voluntary vertical gaze, with later paralysis of horizontal gaze; oculocephalic and oculovestibular reflexes are preserved. Vertical saccades may initially be slowed. Postural instability, marked akinesia, and unexplained falls also occur early and may precede vertical gaze palsies. In addition, the neck often assumes an extended posture (axial dystonia in extension), with resistance to passive flexion. Rigidity of the limbs and bradykinesia may mimic Parkinson disease, but tremor is less common or conspicuous. A coexisting pseudobulbar palsy produces facial weakness, dysarthria, dysphagia, and often exaggerated jaw jerk and gag reflexes; there may also be exaggerated and inappropriate emotional responses (pseudobulbar affect). Hyperreflexia, extensor plantar responses, and cerebellar signs are sometimes seen. The dementia of progressive supranuclear palsy is characterized by forgetfulness, slowed thought processes, alterations of mood and personality, and impaired calculation and abstraction. Sleep disturbances, especially insomnia, are common.
Some patients with pathologically verified disease have pure akinesia or a clinical phenotype resembling Parkinson disease; others resemble corticobasal degeneration, with dystonia, apraxia, and cortical sensory loss.
MRI may show midbrain atrophy (hummingbird sign).
Parkinson disease differs from the classic form of progressive supranuclear palsy in that voluntary downward and horizontal gaze are not usually lost, axial posture tends to be characterized by flexion rather than extension, tremor is common, the course is less fulminant, and antiparkinsonian medications are more often effective.
Dopaminergic preparations may benefit rigidity and bradykinesia, especially in the first 1 or 2 years. Anticholinergics such as amitriptyline 50 to 75 mg orally at bedtime or benztropine 6 to 10 mg/d orally can improve speech, gait, and pathologic laughing or crying. Pseudobulbar affect is best treated with a commercial preparation containing dextromethorphan and quinidine sulfate (20 mg/10 mg capsules). Methysergide 8 to 12 mg/d orally may ameliorate dysphagia. There is no treatment for the dementia. Treatment is supportive.
The disorder typically follows a progressive course, with death from aspiration or inanition within 2 to 12 (usually 6-10) years.
LI. Progressive supranuclear palsy. Semin Neurol. 2014;34:151–159.
Corticobasal degeneration is a rare, nonfamilial, degenerative disorder, a tauopathy that occurs in middle-aged or elderly persons of either sex. It is characterized pathologically by the presence of abnormal intracellular filamentous deposits containing tau protein. It sometimes simulates Parkinson disease when bradykinesia and rigidity are conspicuous features. Postural-action tremor may also occur, but the usual cause of profound disability is limb apraxia and clumsiness rather than extrapyramidal deficits. Other clinical features include speech disturbances (aphasic, apraxic, or dysarthric), acalculia, cortical sensory deficits (eg, neglect syndromes), stimulus-sensitive myoclonus, alien limb phenomenon (the tendency for a limb to move semipurposefully, involuntarily, and without the knowledge of its owner), dysphagia, postural disturbances, dystonic features, and ultimately cognitive decline and behavioral changes. Frontal release signs, brisk tendon reflexes, and extensor plantar responses may also be encountered. There is increased saccadic latency, but saccades are of normal velocity.
Some pathologically verified cases present with a frontal behavioral-spatial disorder, a nonfluent/agrammatic variant of primary progressive aphasia, or the phenotype of progressive supranuclear palsy.
The disorder is distinguished from Parkinson disease by the marked apraxia that often leads to a useless limb, difficulty in opening or closing the eyes, or speech disturbances. The presence of pyramidal and cortical deficits in addition to any extrapyramidal dysfunction also helps in this regard, but definitive diagnosis can be made only at autopsy. MRI may show cortical, callosal, and midbrain atrophy and enlargement of the third ventricle. SPECT reveals hypoperfusion in regions of the frontal and parietal lobes.
No specific therapy exists, and treatment is generally supportive. Antiparkinsonian medication is sometimes helpful for treating bradykinesia and rigidity, but often the response is disappointing. There is no treatment for the limb apraxia. Botulinum toxin may help focal dystonic features. Physical therapy is sometimes worthwhile.
The disorder follows a progressive course, leading to increasing disability and dependence. Death typically follows within 10 years, often sooner, from aspiration pneumonia.
et al.. Criteria for the diagnosis of corticobasal degeneration. Neurology. 2013;80:496–503.
Huntington disease is a hereditary disorder of the nervous system characterized by the gradual onset and subsequent progression of chorea and dementia. It occurs throughout the world and in all ethnic groups. Its prevalence rate is approximately 5 per 100,000 population. Symptoms usually do not appear until adulthood (typically between 30 and 50 years of age), by which time these patients have often started families of their own; thus the disease continues from one generation to the next.
Huntington disease is an autosomal dominant disorder due to a mutation in the huntingtin gene (HTT). The disease shows complete penetrance, so that offspring of an affected individual have a 50% chance of developing it. Additional features of the inheritance of Huntington disease include anticipation, meaning that there is a trend toward earlier onset in successive generations, and paternal descent, which refers to the tendency for anticipation to be most pronounced in individuals who inherit the disease from their father. Both phenomena relate to the unstable nature of the mutation responsible for Huntington disease—expansion of a CAG trinucleotide repeat that codes for a polyglutamine tract. The repeat can expand during gametogenesis, especially in the male germline. This leads to an abnormal protein with longer and longer polyglutamine tracts. Normal subjects have between 9 and 37 CAG repeats, whereas nearly all patients with Huntington disease have more than 40. The age of disease onset depends on the length of the CAG repeat, but genetic polymorphisms are also associated with age of onset.
When a positive family history cannot be obtained, this may be because of the early death of a parent; moreover, relatives often conceal the familial nature of the disorder. In addition, a certain degree of eccentric behavior, clumsiness, or restlessness may be regarded as normal by lay people and medical personnel unfamiliar with the disorder. Therefore, the family history should not be regarded as negative until all close relatives of the patient have been examined personally. Nevertheless, apparently sporadic cases are occasionally encountered.
Postmortem examination reveals cell loss, particularly in the cerebral cortex and corpus striatum (Figure 11-6). In the latter region, medium-sized spiny neurons that contain γ-aminobutyric acid (GABA) and enkephalin and project to the external segment of the globus pallidus are affected earliest, but other classes of neurons are eventually involved as well. Biochemical studies have shown that concentrations of the inhibitory neurotransmitter GABA, its biosynthetic enzyme glutamic acid decarboxylase (GAD), and acetylcholine and its biosynthetic enzyme choline acetyltransferase are all reduced in the basal ganglia of patients with the disease. The concentration of dopamine is normal or slightly increased. Changes in the concentrations of certain neuropeptides in the basal ganglia have also been found. PET has shown reduced glucose utilization, even in an anatomically normal caudate nucleus.
Schematic representation of the sequence of neurons involved in Huntington disease. A: Dopaminergic neurons (red) originating in the substantia nigra normally inhibit the GABAergic output from the striatum (caudate and putamen), whereas cholinergic neurons (green) exert an excitatory effect. B: In Huntington disease, GABAergic neurons (black) are preferentially lost, resulting in reduced inhibitory output from the striatum. (Used with permission from Aminoff MJ. Pharmacologic management of parkinsonism and other movement disorders. In: Katzung BG, Masters SB, Trevor AJ, eds. Basic and Clinical Pharmacology. 12th ed. New York, NY: McGraw-Hill; 2012.)
Symptoms usually begin in the fourth or fifth decade, and the disease is progressive, with an average life span after onset of approximately 15 years.
Either abnormal movements or intellectual changes may be the initial symptom, but ultimately both are present. Neurodegeneration commences many years earlier and may be accompanied by subtle cognitive, psychiatric, or motor changes that are only apparent in retrospect.
Dementia—The earliest mental changes often consist of irritability, moodiness, and antisocial behavior, but a more obvious dementia subsequently develops. This is characterized at an early stage by selective and progressive impairment of attention and executive function, consistent with frontostriatal pathology.
Chorea—Movement disturbance may be characterized initially by no more than an apparent fidgetiness or restlessness, but grossly abnormal choreiform or choreoathetoid movements are eventually seen.
Atypical forms—Especially in cases developing during childhood—but occasionally in adult-onset cases as well—the clinical picture is dominated by progressive rigidity and akinesia, with little or no chorea. This is known as the Westphal variant, and the correct diagnosis is suggested by the accompanying dementia and positive family history. Epilepsy and cerebellar ataxia are frequent features of the juvenile form but not of adult cases.
Genetic testing provides a definitive means of establishing the diagnosis and also permits presymptomatic detection of the disease. It should be preceded and followed by genetic counseling.
CT scanning or MRI often demonstrates atrophy of the cerebral cortex and caudate nucleus in established cases. Reduction in striatal metabolic rate may be demonstrated by PET.
Conditions that should be considered in the differential diagnosis of Huntington disease are listed in Table 11-2. Tardive dyskinesia (discussed later), which is most common, can usually be identified from the history. Laboratory studies can exclude most medical disorders associated with chorea. Other hereditary disorders with chorea are considered later.
Huntington disease-like (HDL) disorders resemble Huntington disease but are not associated with abnormal CAG trinucleotide repeat number of the huntingtin gene. Autosomal dominant (HDL1 and HDL2) and recessive forms (HDL3) have been described. HDL1 is associated with a 192-nucleotide insertion, resulting in an expanded octapeptide repeat, in the prion protein gene (PRNP). HDL2 is caused by an expanded CAG/CTG repeat in the junctophilin-3 gene (JPH3).
Benign hereditary chorea is inherited in an autosomal dominant manner or occurs de novo and is characterized by choreiform movements that develop in early childhood, do not progress during adult life, and are not associated with dementia. An autosomal recessive form may also exist. In patients with mutations in the gene (NKX2-1) coding for thyroid transcription factor-1, hypothyroidism and pulmonary abnormalities may also be present (brain–thyroid–lung syndrome).
Familial chorea sometimes occurs in association with circulating acanthocytes (spiny red blood cells), but examination of a wet blood film will clearly distinguish this disorder, discussed later. Other clinical features of chorea-acanthocytosis include orolingual ticlike dyskinesias, vocalizations, mild intellectual decline, seizures, peripheral neuropathy, and muscle atrophy. Parkinsonian features are sometimes present. Unlike certain other disorders associated with circulating acanthocytes, there is no disturbance of β-lipoprotein concentration in the peripheral blood.
Paroxysmal choreoathetosis may occur on a familial basis, but the intermittent nature of the symptoms and their relationship to movement or emotional stress usually distinguish this disorder from Huntington disease.
Wilson disease can be distinguished from Huntington disease by the mode of inheritance, the presence of Kayser-Fleischer rings, and abnormal serum copper and ceruloplasmin levels.
Dentatorubral-pallidoluysian atrophy, another dominantly inherited CAG repeat disorder that is clinically similar to Huntington disease, is distinguished by genetic testing.
Neuroferritinopathy (NBIA2) is considered later. Although characterized by progressive chorea and dystonia with onset in adults having a positive family history, cognitive function is relatively preserved, MRI is characteristically abnormal, and the mutant gene (FTL1) is distinct from the Huntingtin gene.
The age at onset of symptoms usually distinguishes Huntington disease from certain rare inherited childhood disorders characterized by choreoathetosis.
When the early symptoms constitute progressive intellectual failure, it may not be possible to distinguish Huntington disease from other varieties of dementia unless the family history is characteristic or the movement disorder becomes noticeable.
There is no cure for Huntington disease, which, as a rule, terminates fatally 10 to 20 years after clinical onset. There is no treatment for the dementia, but the movement disorder may respond to drugs that interfere with dopaminergic inhibition of striatal output neurons. These include drugs that deplete dopamine from nerve terminals, such as reserpine 0.5 to 5 mg/d orally or tetrabenazine 12.5 to 50 mg orally three times daily, and dopamine D2-receptor–blocking drugs such as haloperidol 0.5 to 4 mg orally four times daily or atypical antipsychotic agents such as quetiapine (increasing from 25 mg daily up to 100 mg twice daily as tolerated). Quetiapine is also used to treat psychosis or disruptive behavior, as is olanzapine or risperidone. In some patients, clozapine can be tried but necessitates weekly blood counts. Drugs that potentiate GABAergic or cholinergic neurotransmission are generally ineffective. The role of deep brain stimulation is uncertain. Selective serotonin reuptake inhibitors may help to reduce depression, aggressiveness, and agitation. Social services are helpful in management.
Patients should be advised of the risk of transmitting the disease to offspring, and living offspring should receive genetic counseling. The use of genetic markers for detection of presymptomatic Huntington disease may present ethical concerns about adverse psychologic reactions or potential misuse of such information by others to the individual’s detriment.
et al.. Huntington disease: natural history, biomarkers and prospects for therapeutics. Nat Rev Neurol. 2014;10:204–216.
This disorder, which is inherited in an autosomal dominant manner, is rare except in Japan. It is characterized by dementia, choreoathetosis, ataxia, and myoclonic epilepsy. The mutant gene, atrophin 1 (ATN1), is distinct from that in Huntington disease, despite the similarity of clinical phenotype. Mutant ATN1 contains an expanded CAG repeat, the size of which correlates with age at onset and disease severity. Treatment is symptomatic, as for Huntington disease.
Sydenham chorea occurs principally in children and adolescents as a complication of a previous group A hemolytic streptococcal infection. It is the most common cause of chorea developing acutely in children. The underlying pathologic feature is probably an arteritis. In approximately 30% of cases, it appears 2 or 3 months after an episode of rheumatic fever or polyarthritis, but in other patients no such history can be obtained. There is usually no recent history of sore throat and no fever. The disorder may have an acute or insidious onset, usually subsiding within the following 4 to 6 months. It may recur during pregnancy (chorea gravidarum), however, or in patients taking oral contraceptive preparations.
Sydenham chorea is characterized by abnormal choreiform movements that are sometimes unilateral and, when mild, may be mistaken for restlessness or fidgetiness. There may be accompanying behavioral changes, with the child becoming irritable or disobedient. Obsessive-compulsive symptoms and emotional lability also occur. In 30% of cases there is evidence of cardiac involvement, but the sedimentation rate and antistreptolysin O titer are usually normal. The diagnosis is supported by the presence of other manifestations of rheumatic fever and by the absence of any other cause for the chorea such as systemic lupus erythematosus. Cerebral MRI or CT findings are usually normal. PET and SPECT studies show reversible basal ganglia hypermetabolism.
The traditional treatment is bed rest, sedation, and prophylactic antibiotic therapy even if there are no other signs of acute rheumatism. A course of intramuscular penicillin is generally recommended, and continuous prophylactic oral penicillin daily or intramuscular benzathine penicillin G monthly until approximately age 20 years is also frequently advised to prevent streptococcal infections. If necessary, chorea can be treated with haloperidol, risperidone, or other dopamine receptor–blocking drugs, or with valproic acid or carbamazepine, depending on its severity. In severe cases unresponsive to other measures, a course of corticosteroids may be effective. The prognosis is essentially that of the cardiac complications.
PANDAS (pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections) is the acronym used to refer to the association of obsessive-compulsive or tic disorders of variable severity with streptococcal infections in children. In addition, dystonia, chorea and dystonic choreoathetosis may be sequelae of streptococcal infection. The etiology is unclear but may be similar to that of Sydenham chorea, relating to poststreptococcal autoimmunity.
F. Sydenham’s chorea. Handb Clin Neurol. 2011;100:221–229.
ISOLATED GENERALIZED TORSION DYSTONIA
This disorder is characterized by dystonic movements and postures and an absence of other neurologic signs. The birth and developmental histories are normal. Before the diagnosis can be made, other possible causes of dystonia must be excluded on clinical grounds and by laboratory investigations.
Isolated generalized torsion dystonia is typically inherited as an autosomal dominant disorder with variable penetrance of 30% to 40%. Molecular genetic techniques permit identification of carriers of the responsible deletion in torsin 1A, an ATP-binding protein, but there is some evidence of genetic heterogeneity. Other dystonic disorders (discussed later) occur as autosomal or X-linked recessive disorders. Changes in the concentrations of norepinephrine, serotonin, and dopamine occur in a variety of brain regions, but their role in the pathogenesis of dystonia is uncertain. Onset may be in childhood or later life, and the disorder remains as a lifelong affliction. The diagnosis is made on clinical grounds.
When onset is in childhood, a family history is usually obtainable. Symptoms generally commence in the legs. Progression is likely, and the disorder typically leads to severe disability from generalized dystonia.
With onset in adult life, a positive family history is less likely. The initial symptoms are usually in the arms or axial structures. Generalized dystonia may ultimately develop in approximately 20% of patients with adult-onset dystonia, but severe disability does not usually occur.
The disorder is characterized by abnormal movements and postures that are typically exacerbated by voluntary activity. For example, the neck may be twisted to one side (torticollis), the arm held in a hyperpronated position with the wrist flexed and fingers extended, the leg held extended with the foot plantar-flexed and inverted, or the trunk held in a flexed or extended position. There is often facial grimacing, and other characteristic facial abnormalities may also be encountered, including blepharospasm (spontaneous, involuntary forced closure of the eyelids for a variable time; difficulty in eye opening; repetitive blinking) and oromandibular dystonia. This consists of spasms of the muscles about the mouth, causing, for example, involuntary opening or closing of the mouth; pouting, pursing, or retraction of the lips; retraction of the platysma muscle; and roving or protruding movements of the tongue. The combination of blepharospasm and oromandibular dystonia is sometimes referred to as Meige syndrome.
Other causes of dystonia (see Table 11-3) must be distinguished before a diagnosis of isolated torsion dystonia is made. A normal developmental history before the onset of abnormal movements, an absence of other neurologic signs, and normal results of laboratory investigations, are important. Drug-induced dystonia can generally be excluded by the history. Imaging may reveal acquired brain lesions. Genetic testing in conjunction with genetic counseling is helpful by obviating the need for other diagnostic studies and facilitating further management in patients with isolated torsion dystonia that begins before 30 years of age or in older subjects with a positive family history.
The abnormal movements may be helped, at least in part, by drugs. A dramatic response to levodopa suggests a variant of classic torsion dystonia, discussed separately later. Anticholinergic drugs given in the highest doses that can be tolerated (typically, trihexyphenidyl 40-50 mg/d orally in divided doses) may be very effective. Diazepam is occasionally helpful. Phenothiazines, haloperidol, or tetrabenazine may be worthwhile; however, at effective doses, these drugs usually lead to mild parkinsonism. Baclofen and carbamazepine are sometimes helpful. Stereotactic thalamotomy may help patients with predominantly unilateral dystonia involving the limbs. Deep brain stimulation of the globus pallidus has benefitted a number of patients and should be considered in medically refractory cases. Potential adverse events include infection at the stimulator site, broken leads, hemorrhage, affective changes, and dysarthria.
Approximately one-third of patients eventually become confined to chair or bed, and another one-third are affected only mildly. In general, severe disability is more likely to occur when the disorder commences in childhood.
J. Medical treatment of dystonia. Mov Disord. 2013;28:1001–1012.
SB. Genetic and clinical features of primary torsion dystonia. Neurobiol Dis. 2011;42:127–135.
This disorder (Segawa syndrome) is inherited in an autosomal dominant manner with incomplete penetrance (GCH1 gene) or, rarely, as an autosomal recessive trait (TH gene). Symptom onset is typically in childhood but may occur later. Girls are affected more commonly than boys. Disabling dystonia may be accompanied by bradykinesia and rigidity that sometimes leads to a mistaken diagnosis of juvenile Parkinson disease; diurnal worsening of symptoms is common. Extensor plantar response or other evidence of upper motor neuron involvement may occur. Some patients have focal dystonias or minor functional deficits, whereas others become chair-bound if untreated. Remarkable recovery occurs with low doses of levodopa, to which patients are particularly sensitive. Because of the wide variation in age and manner of presentation, all children with an unexplained extrapyramidal motor disorder and all patients with symptoms that might relate to dopa-responsive dystonia probably merit a trial of levodopa therapy.
M. Dopa-responsive dystonia. Handb Clin Neurol. 2011;100:539–557.
An X-linked recessive form of dystonia-parkinsonism (sometimes called lubag) has been identified in men from the Philippines and relates to mutations of TAF1 gene at Xq13.1 Female heterozygotes are reported to have mild dystonia or chorea. The response to pharmacotherapy is often disappointing. Another variety with autosomal dominant inheritance has been described in patients of differing ethnic origin, with rapid evolution of symptoms and signs over hours, days, or weeks, but slow progression thereafter; a rostrocaudal (face, arm, leg) gradient of involvement may be noted. The disorder relates to mutation in the gene encoding the alpha-3 subunit of N,K-ATPase (ATP1A3) on chromosome 19q13. It may first manifest during childhood or adulthood, often after a period of stress. Levodopa therapy is ineffective.
This is an autosomal dominant disorder with incomplete penetrance and variable expression, related to mutations in the DRD2 or SGCE gene. Patients exhibit rapid jerks in addition to more sustained abnormal postures. The legs are often spared. The jerks may respond to alcohol. The EEG is normal. The disorder appears to be distinct from classic isolated torsion dystonia. It usually begins before 20 years of age and has a benign, slowly progressive course over many years. Genetic studies suggest that myoclonic dystonia and essential myoclonus are allelic disorders.
Some of the dystonic features of generalized torsion dystonia may occur as localized phenomena. They are probably best regarded as focal dystonias that occur as formes frustes of the more generalized disorder in patients with a positive family history or that represent a focal manifestation of its adult-onset form when there is no family history. In addition, focal adult-onset dystonia may exhibit autosomal dominant inheritance.
Both blepharospasm and oromandibular dystonia can occur as isolated focal dystonias. Familial blepharospasm inherited as an autosomal dominant trait has been described, but the gene remains unmapped.
Spasmodic torticollis usually begins in the fourth or fifth decade and is characterized by a tendency for the neck to twist to one side. This often occurs episodically in early stages, but eventually the neck is held continuously to one side. Sensory tricks (eg, light touch of the face) may help to reduce the intensity of symptoms. Neck and shoulder pain are common, and a head tremor may be present. Although the disorder is usually lifelong, spontaneous remission does occur occasionally, especially in the first 18 months after onset. Medical treatment is generally unsatisfactory. A trial of the drugs used for more generalized torsion dystonias is worthwhile. The most effective treatment, however, is with local injection of botulinum toxin into the overactive muscles; benefit lasts for up to several months, after which the injection is repeated as needed. Selective section of the spinal accessory (XI) nerve and the upper cervical nerve roots may help patients in whom the neck is markedly deviated to the side, but recurrence of the abnormal posture is frequent.
Writer’s cramp is characterized by dystonic posturing of the hand and forearm when the hand is used for writing and sometimes for other tasks (eg, playing the piano or using a screwdriver or table cutlery). Anticholinergic medications, baclofen, or benzodiazepines may help occasionally. Injections of botulinum toxin into the involved muscles are often helpful, but hand or arm weakness may be a troublesome consequence. Patients may have to learn to use the other hand for writing or other fine motor tasks, although in some cases this hand also becomes affected. The use of a pen with a large handle is sometimes worthwhile; in other instances, patients may use a keyboard.
A large group of disorders are characterized by dystonia combined with other neurologic features, such as dementia, ataxia, dyskinesias, or parkinsonism. This includes Wilson disease, which is discussed separately.
Fahr disease consists of idiopathic basal ganglia calcification associated with dystonia, parkinsonism, and behavioral disturbances; autosomal dominant inheritance occurs in some families.
Neurodegeneration with brain iron accumulation (NBIA) refers to a group of inherited disorders with iron accumulation in the basal ganglia. Clinical manifestations include extrapyramidal and pyramidal deficits, neuropsychiatric changes, and ocular abnormalities. Age of onset, mode of inheritance, and rate of progression varies. Genetic testing identifies particular disorders. Pantothenate kinase-associated neurodegeneration (or NBIA1) is characterized by gait abnormalities, dystonia, spasticity, hyperreflexia, extensor plantar responses, behavioral changes, dysarthria, dysphagia, and ocular abnormalities (eg, retinal degeneration, gaze palsies, optic atrophy). Deposition of iron and other pigments in the globus pallidus leads to a characteristic MRI appearance on T2-weighted MRI called the “eye of the tiger” sign (Figure 11-7). The disorder has autosomal recessive inheritance and results from mutations in the gene for pantothenate kinase 2 (PANK2). Neuroferritinopathy (NBIA2) is a rare, adult-onset, dominantly inherited, progressive disorder related to mutations in the ferritin light chain gene (FTL1). It is characterized initially by chorea, dystonia (predominantly in the legs), parkinsonism, or some combination of these, with deficits subsequently becoming generalized. Cognitive features may be subtle initially, but disinhibition and emotional lability are common even at an early stage. An action-specific facial dystonia (involving symmetric frontalis and platysma contraction, giving a startled appearance) is characteristic. MRI shows excess iron in the basal ganglia, and later cavitation in the caudate and putamen.
Pantothenate kinase-associated neurodegeneration (formerly Hallervorden-Spatz disease) showing the “eye of the tiger” sign. T2-weighted image shows bilateral symmetric hyperintense signal changes in the anterior medial globus pallidus representing gliosis, demyelination, neuronal loss, and axonal swelling. The surrounding hypointensity in the globus pallidus is secondary to iron deposition. (Used with permission from A. DiBernardo.)
Chorea-acanthocytosis is characterized by some combination of dystonia, chorea, orofacial dyskinesias, parkinsonism, tics, hyporeflexia, amyotrophy, and cognitive abnormalities. Dysexecutive syndromes, obsessive-compulsive disorder, depression, and psychosis may all occur. The peripheral blood contains circulating acanthocytes (spiny red cells) but a normal lipid profile. The disorder has autosomal recessive inheritance and is caused by mutation in the VPS13A gene.
Certain mitochondrionopathies may also be associated with dystonia, such as Leber hereditary optic atrophy.
Dystonia may occur as a somatoform or conversion disorder. Anxiety, depression, a personality disorder, or some combination of these and other psychiatric disturbances may be present. However, anxiety and depression are common consequences of dystonia that has an organic basis. Features that help to support a diagnosis of psychogenic dystonia include variable and inconsistent findings, findings that are incongruent with those of organic dystonia, a known psychologic precipitating factor, excessive pain, a prior history of somatoform disorder, other psychogenic signs (eg, nonanatomic sensory loss), multiple somatizations, abnormal posturing that disappears with distraction, lack of sensory tricks (to relieve the dystonia) and overflow dystonia, onset in the lower limbs in adults, and an impairment of function that is out of proportion to the dystonia and is selective in a manner that is difficult to explain (eg, limits the ability to work but not the ability to dress and attend to other activities of daily living). Symptoms may be relieved by psychotherapy, suggestion, or treatment with a placebo. Video surveillance may reveal a discrepancy between reported disability and the patient’s actual clinical state. Treatment is of the underlying psychiatric disorder.
AE. Psychogenic movement disorders. Curr Opin Neurol. 2005;18:399–404.
In this group of disorders, dystonia and dyskinesias occur episodically, often on a familial basis (Table 11-8). The familial disorders are classified by whether they are induced by movement, as discussed later. Paroxysmal dyskinesias may also occur with basal ganglia pathology, multiple sclerosis, cerebral palsy, thyroid dysfunction, or idiopathic hypoparathyroidism; an MRI, EEG, and laboratory studies may then be necessary to clarify the nature of the underlying disorder. Treatment is of the underlying disorder. Hypnogenic paroxysmal dyskinesia is a form of frontal lobe epilepsy characterized by intermittent dystonia and choreoathetoid movements during sleep; it responds well to antiseizure medication.
Table 11-8.Paroxysmal Dyskinesias. |Favorite Table|Download (.pdf) Table 11-8. Paroxysmal Dyskinesias.
| ||Paroxysmal Nonkinesigenic Dyskinesia ||Paroxysmal Kinesigenic Choreoathetosis ||Paroxysmal Exercise-Induced Dyskinesia |
|Gene ||MR1 ||PRRT2 ||SLC2A1 |
|Inheritance ||AD ||AD or sporadic ||Sporadic or ?AD |
|Precipitants ||Caffeine; alcohol; fatigue; stress; hunger; menstruation ||Sudden movement or startle ||Exercise (eg, walking for 30 minutes) or physical exertion |
|Usual age at onset ||Before 30 years ||Before 20 years ||Before 30 years |
|Duration of episodes ||Minutes – hours ||Seconds – minutes ||Minutes, hours (commonly 5-30 minutes) |
|Frequency ||1-3/day; may be long episode-free intervals ||Variable; may be many/day ||1/day—1/month |
|Manifestations ||Choreoathetosis; dystonia. May be unilateral and then generalize ||Choreoathetosis; dystonia. Usually unilateral ||Dystonia in exercised limbs. May be unilateral |
|Treatment ||Sleep; clonazepam (anticonvulsants sometimes helpful) ||Anticonvulsants (carbamazepine; phenytoin) ||Usually unhelpful |
|Secondary causes (uncommon) ||Multiple sclerosis; trauma; endocrinopathy; vascular disease ||Multiple sclerosis; trauma; endocrinopathy ||Trauma; insulinoma |
PAROXYSMAL NONKINESIGENIC DYSKINESIA
Dystonia, chorea, and athetosis lasting from a few minutes to several hours characterize this disorder, which is inherited as an autosomal dominant trait with incomplete penetrance. Affected patients are likely to harbor mutations in the myofibrillogenesis regulator 1 (MR1) gene. Attacks may occur several times daily and are precipitated by caffeine, alcohol, fatigue, hunger, and emotional stress but not by movement. Onset may be in childhood or early adulthood. Examination between episodes is normal. Treatment is with clonazepam.
PAROXYSMAL KINESIGENIC CHOREOATHETOSIS
This disorder occurs on a sporadic basis or as an autosomal dominant trait. The gene (PRRT2) has been mapped to chromosome 16. There may be a history of convulsions in infancy. Attacks begin in the first or second decade, last for seconds to minutes, and are precipitated by sudden movement. They often respond to anticonvulsant medication, especially carbamazepine.
PAROXYSMAL EXERCISE-INDUCED DYSKINESIAS
In this rare disorder, which may be sporadic or familial, dystonia is brought on by exercise (as opposed to the initiation of movement) and affects the exercised limb. Onset is usually before 30 years of age ; attacks last for several minutes to hours and are poorly responsive to medication. The disorder has been related to mutations in the solute carrier family 2 (facilitated glucose transporter), member 1 gene (SLC2A1). Pharmacologic treatment is usually unhelpful.
Wilson disease is an autosomal recessive disorder of copper metabolism that produces neurologic and hepatic dysfunction. The affected gene (ATP7B) codes for the beta polypeptide of copper-transporting ATPase. Although the precise nature of the biochemical abnormality in Wilson disease is unknown, its pathogenesis appears to involve decreased binding of copper to the transport protein ceruloplasmin. As a result, large amounts of unbound copper enter the circulation and are subsequently deposited in tissues, including the brain, liver, kidney, and cornea. Studies of mitochondrial function and aconitase activity suggest that free radical formation and oxidative damage, perhaps through mitochondrial copper accumulation, are important in pathogenesis.
Wilson disease usually presents in childhood or young adult life. The average age at onset is approximately 11 years for patients presenting with hepatic dysfunction and 19 years for those with initial neurologic manifestations, but the disease may begin as late as the sixth decade. Hepatic and neurologic presentations are about equally common, and most patients, if untreated, eventually develop both types of involvement. Rare presentations include joint disease, fever, hemolytic anemia, and behavioral disturbances.
Ocular and hepatic abnormalities are the most prominent non-neurologic manifestations of Wilson disease. The most common ocular finding is Kayser-Fleischer rings (Figure 11-8): bilateral brown corneal rings that result from copper deposition in Descemet membrane. The rings are present in virtually all patients with neurologic involvement but may be detectable only by slit lamp examination. Hepatic involvement leads to chronic cirrhosis, which may be complicated by splenomegaly, esophageal varices with hematemesis, or fulminant hepatic failure. Splenomegaly may cause hemolytic anemia and thrombocytopenia.
Kayser-Fleischer ring in Wilson disease. This corneal ring is brown and located at the outer edge of the gray-blue iris. Its darkness increases as the outer border (limbus) of the cornea is approached. (Used with permission from Usatine R, Smith MA, Mayeux EJ Jr, Chumley H, Tysinger J, eds. The Color Atlas of Family Medicine. New York, NY: McGraw-Hill; 2008.)
Neurologic findings reflect the disproportionate involvement of the caudate nucleus, putamen, cerebral cortex, and cerebellum. Neurologic signs include resting or postural tremor, choreiform movements of the limbs, facial grimacing, rigidity, hypokinesia, dysarthria, dysphagia, abnormal (flexed) postures, and ataxia. Seizures may occur. Psychologic disorders include dementia, characterized by mental slowness, poor concentration, and memory impairment; disorders of affect, behavior, or personality; and (rarely) psychosis with hallucinations. There is a tendency for a dystonic or parkinsonian picture with hyperreflexia and extensor plantar responses to predominate when the disease begins before 20 years of age—and for older patients to exhibit wild tremor, chorea, or ballismus. Symptoms may progress rapidly, especially in younger patients, but are more often gradual in development with periods of remission and exacerbation.
When Wilson disease presents as a neurologic disorder, other conditions that must be considered in the differential diagnosis include other causes of movement disorders, multiple sclerosis, and juvenile-onset Huntington disease.
Investigation may reveal abnormal liver function blood tests and aminoaciduria as a result of renal tubular damage. The levels of serum copper and ceruloplasmin (an a2-globulin to which 90% of the circulating copper is bound) are low, and 24-hour urinary copper excretion is generally increased. Liver biopsy reveals a huge excess of copper; it also usually reveals cirrhosis. No single laboratory feature is reliable in isolation. Brain CT scanning or MRI (Figure 11-9) may show cerebrocortical atrophy and abnormalities in the basal ganglia. The MRI abnormalities include the “face of the giant panda” sign in the midbrain and sometimes a “face of the miniature panda” in the pontine tegmentum.
MRI of a 31-year-old woman with Wilson disease. T2 hyperintensity involving the basal ganglia and thalamus bilaterally is shown. Other images showed T2 hyperintensity of the dorsal midbrain and central pons, T1 shortening involving the basal ganglia bilaterally, and diffuse cerebral atrophy. (Used with permission from A. Gean.)
The optimal means of removing copper from the brain and other organs is disputed. Most physicians use penicillamine, a copper-chelating agent that promotes extraction of copper from tissue deposition sites, even though instances of penicillamine-induced worsening have been described. Treatment should be started as early as possible and customarily employs approximately 1.5 g/d of orally administered penicillamine, taken in divided doses about 1 to 2 hours before meals to maximize absorption. The response to treatment may take several months and can be monitored by serial slit lamp examinations and blood chemistries. Side effects of penicillamine include nausea, nephrotic syndrome, myasthenia gravis, arthropathy, pemphigus, diverse blood dyscrasias, and a lupuslike syndrome.
Trientine hydrochloride, another chelating agent, can be given in a daily dose of 1 to 1.5 g (divided into two or three doses) and is less likely than penicillamine to cause drug reactions or neurologic deterioration. Treatment with tetrathiomolybdate may be even more effective in preserving neurologic function, but it is not yet available commercially.
Restriction of dietary copper (to less than 2 mg daily) is important but is insufficient as sole treatment. Administration of zinc acetate (150 mg/d orally) or zinc sulfate (200 mg/d orally) decreases copper absorption. The main advantage of zinc is low toxicity compared with other anticopper agents, although it may cause gastric irritation when introduced.
Treatment must be continued for the lifetime of the patient. Most patients treated early can expect a complete or nearly complete recovery. Liver transplantation may be required in cases with fulminant hepatic failure.
Siblings of affected patients should be screened for presymptomatic Wilson disease with neurologic and slit lamp examinations and determination of serum ceruloplasmin levels. If no abnormalities are found, serum copper and urinary copper excretion should be assayed and liver biopsy performed if necessary. Mutation analysis allows for screening family members when the index case has a known mutation. If these investigations reveal preclinical Wilson disease, therapy should be instituted as described previously for symptomatic disease.
RF. Wilson’s disease. Handb Clin Neurol. 2011;100:681–709.
DRUG-INDUCED MOVEMENT DISORDERS
Parkinsonism frequently complicates treatment with dopamine-depleting agents such as reserpine or dopamine-receptor antagonists such as phenothiazines or butyrophenones. With antipsychotic drugs, the risk of this complication is greatest when agents are used that are potent D2-receptor antagonists with little anticholinergic effect, such as piperazine phenothiazines, butyrophenones, and thioxanthenes (Table 11-9). In addition, women and elderly patients appear to be at somewhat increased risk. Tremor is relatively uncommon. Hypokinesia tends to be symmetric and the most conspicuous neurologic feature. These points, and the history of drug ingestion, often suggest the iatrogenic nature of the disorder. Signs usually develop within 3 months after starting the offending drug and disappear over weeks or months after discontinuance.
Table 11-9.Antipsychotic Drug-Induced Extrapyramidal Side Effects. |Favorite Table|Download (.pdf) Table 11-9. Antipsychotic Drug-Induced Extrapyramidal Side Effects.
|Drug ||Relative EPS Risk1 |
|First-generation (typical) antipsychotics |
|Fluphenazine ||Prolixin ||High |
|Haloperidol ||Haldol ||High |
|Perphenazine ||Trilafon ||High |
|Thiothixene ||Navane ||High |
|Trifluoperazine ||Stelazine ||High |
|Chlorpromazine ||Thorazine ||Intermediate |
|Thioridazine ||Mellaril ||Intermediate |
|Second- & third-generation (atypical) antipsychotics |
|Risperidone ||Risperdal ||Intermediate |
|Aripiprazole ||Abilify ||Low |
|Clozapine ||Clozaril ||Low |
|Olanzapine ||Zyprexa ||Low |
|Quetiapine ||Seroquel ||Low |
|Ziprasidone ||Geodon ||Low |
Depending on the severity of symptoms and the necessity for continuing antipsychotic drug therapy, several strategies are available for treating drug-induced parkinsonism. These include slow tapering and eventual withdrawal of the antipsychotic drug, substituting an antipsychotic agent less likely to cause extrapyramidal reactions (see Table 11-9), or adding an anticholinergic drug such as trihexyphenidyl or benztropine (Figure 11-10). Levodopa is of no help if the neuroleptic drugs are continued; it may be helpful if these drugs are discontinued but may then aggravate the psychotic disorder for which they were originally prescribed.
Mechanisms and treatment of drug-induced parkinsonism. Symptoms result from pharmacologic blockade of dopamine receptors by antipsychotic drugs (1), which mimics the degeneration of nigrostriatal dopamine (DA) neurons seen in idiopathic parkinsonism (dashed line). Symptoms may be relieved by the administration of muscarinic anticholinergic drugs (2) or by substituting an antipsychotic drug with anticholinergic properties. These measures restore the normal balance between dopaminergic and cholinergic (ACh) transmission in the striatum.
ACUTE DYSTONIA OR DYSKINESIA
Acute dystonia or dyskinesia (such as blepharospasm, torticollis, or facial grimacing) is an occasional complication of dopamine receptor antagonist treatment, generally occurring within 1 week after introduction of such medication and often within 48 hours. Men and younger patients show increased susceptibility to this complication. The pathophysiologic basis of the disturbance is unclear, but intravenous treatment with an anticholinergic drug (eg, benztropine 2 mg or diphenhydramine 50 mg) usually alleviates it.
Akathisia is a state of motor restlessness characterized by an inability to sit or stand still, which is relieved by moving about. It is a very common movement disorder induced by chronic treatment with antipsychotic drugs and occurs more often in women than in men. It may be seen as a tardive phenomenon after the discontinuation of neuroleptics. Akathisia is treated in the same manner as drug-induced parkinsonism.
Tardive dyskinesia may develop after long-term treatment with antipsychotic dopamine receptor antagonist drugs or with metoclopramide. It is common in chronically institutionalized psychiatric patients, and the risk of developing tardive dyskinesia appears to increase with advancing age.
The underlying pathophysiology is unknown. Drug-induced supersensitivity of striatal dopamine receptors has been proposed but is unlikely to be responsible for several reasons. Supersensitivity always accompanies chronic antipsychotic drug treatment, whereas tardive dyskinesia does not. Supersensitivity may occur early in the course of treatment, whereas tardive dyskinesia does not develop for at least 3 months. In addition, supersensitivity is invariably reversible when drugs are discontinued; tardive dyskinesia is not.
The clinical features of tardive dyskinesia, particularly its persistent nature, are more suggestive of an underlying degenerative abnormality. Such an abnormality may involve GABA neurons, because GABA and its synthesizing enzyme, glutamic acid decarboxylase, are depleted in the basal ganglia after chronic treatment of animals with antipsychotic drugs, and GABA levels in cerebrospinal fluid (CSF) are decreased in patients with tardive dyskinesia.
No consistent pathologic features have been found in the brains of patients with tardive dyskinesia, although inferior olive atrophy, degeneration of the substantia nigra, and swelling of large neurons in the caudate nucleus have been described in some cases.
The clinical disorder is characterized by abnormal choreoathetoid movements that are often especially conspicuous about the face and mouth in adults and tend to be more obvious in the limbs in children. The onset of dyskinesia is generally not until months, or years, after the start of treatment with the responsible agent. Tardive dyskinesia may be impossible to distinguish from such disorders as Huntington disease or isolated torsion dystonia unless a history of drug exposure is obtained.
Tardive dyskinesia is easier to prevent than to cure. Antipsychotic drugs should be prescribed only on clear indication, and their long-term use should be monitored, with periodic drug holidays to determine whether the need for treatment continues. Drug holidays may also help to unmask incipient dyskinesias—which, curiously, tend to worsen when the drug is withdrawn. Antipsychotic medication should be gradually withdrawn if possible when dyskinesia appears during a drug holiday, as this may allow remission to occur.
Treating the established disorder is generally unsatisfactory, although the disorder may resolve spontaneously, especially in children or young adults. Antidopaminergic agents such as haloperidol or phenothiazines suppress the abnormal movements, but their use for this purpose is not recommended because they may aggravate the underlying disorder. Treatment with reserpine 0.25 mg, gradually increased to 2 to 4 mg/d orally, or tetrabenazine 12.5 mg, gradually increased to as much as 200 mg/d orally, taken in divided doses, may be helpful. Both these drugs deplete monoamine neurotransmitters, including dopamine.
A number of other pharmacologic approaches have been suggested and may help in individual cases; these include treatment with carbamazepine, baclofen, valproate, lithium, clonazepam, and alprazolam. Calcium-channel blockers have also been advocated. However, evidence of benefit with these various drugs is inconclusive. Anticholinergic drugs should be avoided, as they may exacerbate the dyskinesia.
Occasional patients with severe dyskinesia have been treated with deep brain stimulation of the globus pallidus or subthalamic nucleus. In patients requiring continued treatment for psychosis, clozapine, risperidone, olanzapine, or quetiapine should be used in place of the typical antipsychotics.
A variety of other late and often persistent movement disorders may appear during the course of antipsychotic drug treatment.
Tardive dystonia is usually segmental in distribution, affecting two or more contiguous body parts, such as the face and neck or arm and trunk. It is less often focal; when this is the case, the head and neck are particularly apt to be affected, producing blepharospasm, torticollis, or oromandibular dystonia. Generalized dystonia is least common and tends to occur in younger patients. Treatment is as for tardive dyskinesia, except that anticholinergic drugs may also be helpful; focal dystonias may also respond to local injection of botulinum A toxin.
Tardive akathisia (characterized by a feeling of restlessness and a need to move about, with an inability to sit or stand still) can also occur; it is treated in the same manner as drug-induced parkinsonism.
Tardive tic, a drug-induced disorder resembling Gilles de la Tourette syndrome (see later), is characterized by multifocal motor and vocal tics. It can be treated in the same manner as Gilles de la Tourette syndrome if symptoms do not remit spontaneously.
Tardive tremor and tardive myoclonus may also occur.
Rabbit syndrome is a neuroleptic-induced disorder characterized by rhythmic vertical movements about the mouth, resembling the chewing movements of a rabbit; the tongue is spared. Anticholinergic drugs may be helpful in its treatment.
AE. Tardive dyskinesia syndromes: current concepts. Parkinsonism Relat Disord. 2014;20 (suppl 1):S113–S117.
PR. Acute and subacute drug-induced movement disorders. Parkinsonism Relat Disord. 2014;20 (suppl 1):S108–S112.
TA. Drug-induced hyperkinetic movement disorders by nonneuroleptic agents. Handb Clin Neurol. 2011;100:347–363.
NEUROLEPTIC MALIGNANT SYNDROME
This rare complication of treatment with antipsychotic drugs (neuroleptics) is manifested by rigidity, fever, altered mental status, and autonomic dysfunction. Haloperidol is implicated most often, but the syndrome can complicate treatment with any antipsychotic drug; whether concomitant treatment with lithium or anticholinergic drugs increases the risk is uncertain. Symptoms typically develop over 1 to 3 days and can occur at any time during the course of treatment.
The differential diagnosis includes infection, which must be excluded in any febrile patient. Neuroleptic malignant syndrome resembles malignant hyperthermia (see Chapter 9, Motor Disorders), but the latter disorder develops over minutes to hours rather than days and is associated with the administration of inhalational anesthetics or neuromuscular blocking agents rather than antipsychotics.
Treatment of neuroleptic malignant syndrome includes withdrawal of antipsychotic drugs, lithium, and anticholinergics; reduction of body temperature with antipyretics and artificial cooling; and rehydration. Dantrolene may be beneficial, as may dopamine agonists, levodopa preparations, or amantadine. The mortality rate is as high as 20%.
CA. Serotonin syndrome vs neuroleptic malignant syndrome: a contrast of causes, diagnoses, and management. Ann Clin Psychiatry. 2012;24:155–162.
OTHER DRUG-INDUCED MOVEMENT DISORDERS
Levodopa produces a wide variety of abnormal movements as a dose-related phenomenon in patients with parkinsonism. They can be reversed by withdrawing the medication or reducing the dose. Chorea may also develop in patients receiving a variety of other medications, including dopamine agonists, anticholinergic drugs, buspirone, phenytoin, carbamazepine, amphetamines, methylphenidate, lithium, and oral contraceptives; it resolves with discontinuance of the responsible drug. Dystonia has resulted from administration of dopamine agonists, lithium, serotonin reuptake inhibitors, carbamazepine, and metoclopramide; and postural tremor from administration of theophylline, caffeine, lithium, thyroid hormone, tricyclic antidepressants, valproic acid, and isoproterenol.
GILLES DE LA TOURETTE SYNDROME
Gilles de la Tourette syndrome, characterized by chronic—typically lifelong—multiple motor and verbal tics, is of unknown cause and does not relate to social class, ethnic group, perinatal abnormalities, birth trauma, or birth order. Symptoms begin before 21 years of age, most often by the age of 11, and the course is one of remission and relapse. Most cases are sporadic, although there is occasionally a family history, and partial expression of the trait may occur in siblings or offspring of patients. Inheritance has been attributed to an autosomal dominant gene with variable penetrance, but inheritance is complex, and risk alleles have been difficult to identify. The prevalence in the United States has been estimated to be 0.05% and the disorder is more common in males than females.
The pathogenesis is obscure, but the corticostriato-thalamocortical pathways seem to be involved. Dopaminergic excess in the brains of patients with Gilles de la Tourette syndrome has been postulated, mainly because of the beneficial effects that dopamine-blocking drugs can have on the tics. The administration of dopamine receptor agonists often fails to produce the exacerbation of symptoms that might be anticipated from this hypothesis, however.
Analysis of linkage in a two-generation pedigree has led to the identification of a rare mutation in the HDC gene encoding histidine decarboxylase, the rate-limiting enzyme in histamine biosynthesis. Such findings suggest a role for histaminergic neurotransmission in the pathogenesis and modulation of Gilles de la Tourette syndrome and tics. No structural basis for the clinical disorder has been recognized.
The first signs consist of motor tics in 80% of cases and vocal tics in 20%; there may be either a single or multiple tics. When the initial sign is a motor tic, it commonly involves the face, as in sniffing, blinking, or forced eye closure. It is generally not possible to make the diagnosis at this stage.
All patients ultimately develop a number of different motor tics and involuntary vocal tics, the latter commonly consisting of grunts, barks, hisses, throat-clearing or coughing, and the like. Vocal tics sometimes take the form of verbal utterances including coprolalia (vulgar or obscene speech), which occurs eventually in approximately half of all patients. There may also be echolalia (parroting the speech of others), echopraxia (imitation of others’ movements), and palilalia (repetition of words or phrases). The tics vary over time in severity, character, and the muscle groups involved. In 40% to 50% of cases, some of the tics involve self-mutilation with such activities as severe nail-biting or hair-pulling, picking at the nose, or biting the lips or tongue. Sensory tics, consisting of pressure, tickling, and warm or cold sensations, also occur. Behavioral disorders, including obsessive-compulsive disorder, attention deficit disorder, learning difficulties, and impulse control disorders, are common in patients with Gilles de la Tourette syndrome, but their precise relationship to the tic disorder is uncertain.
Examination usually reveals no other abnormalities, and the history is therefore of paramount importance. Videotaping of the patient in the home environment may be helpful. There is a higher than expected incidence of left-handedness or ambidexterity. In approximately 50% of cases, the EEG shows minor nonspecific abnormalities of no diagnostic relevance.
The differential diagnosis includes the various movement disorders that can present in childhood. Other disorders characterized by tics (see earlier discussion) are distinguished by resolution of the tics by early adulthood, by the restricted number of tics, or by the context in which the tics occur. Laboratory tests are typically normal, but examination of a wet blood film for acanthocytes, thyroid function tests, and serum copper and ceruloplasmin determination should be considered to exclude other causes. Imaging studies usually are unnecessary unless there are abnormalities other than tics on neurologic examination.
Wilson disease can simulate Gilles de la Tourette syndrome; it must be excluded because it responds well to medical treatment. In addition to a movement disorder, Wilson disease produces hepatic involvement, Kayser-Fleischer corneal rings, and abnormalities of serum copper and ceruloplasmin, which are absent in Gilles de la Tourette syndrome.
Sydenham chorea can be difficult to recognize if there is no recent history of rheumatic fever or polyarthritis and no clinical evidence of cardiac involvement, but this disorder is a self-limiting one, usually clearing in 3 to 6 months.
Bobble-head syndrome, which can be difficult to distinguish from Gilles de la Tourette syndrome, is characterized by rapid, rhythmic bobbing of the head in children with progressive hydrocephalus.
Gilles de la Tourette syndrome is often unrecognized for years, the tics being attributed to psychiatric illness or attention-seeking behavior, or mistaken for some other form of abnormal movement. They may also be mistaken for a general medical disorder, as when sniffing and throat clearing are attributed to allergies. Indeed, in many cases the correct diagnosis is finally made by the family rather than the physician. In consequence, patients are often subjected to unnecessary and expensive treatment before the true nature of the disorder is recognized. Psychiatric disturbances, sometimes culminating in suicide, may occur because of the cosmetic and social embarrassment produced by the tics. Drug therapy can lead to a number of side effects, as discussed next.
Treatment is symptomatic and, if effective, must be continued indefinitely. Education of the patient, family members, and teachers is important. Extra break periods at school and additional time for test taking are often helpful. Cognitive behavioral therapy or other forms of behavioral intervention may be helpful.
Clonidine, an alpha2-adrenergic receptor agonist, has been reported to ameliorate motor or vocal tics in roughly 50% of children so treated. It may act by reducing activity in noradrenergic neurons arising in the locus ceruleus. It is started in a dose of 2 to 3 μg/kg/d, increasing after 2 weeks to 4 μg/kg/d and then, if necessary, to 5 μg/kg/d taken to a daily maximum of 0.3 or 0.4 mg in divided doses. It may cause an initial transient fall in blood pressure. The most frequent side effect is sedation. Other adverse reactions include reduced or excessive salivation and diarrhea. Guanfacine can also be used, starting with 0.5 mg at bedtime and increasing to a maximum of 2 mg twice daily. These alpha-adrenergic agonists have less troublesome side effects than the typical antipsychotics, which are the only therapies for this disorder approved by the US Food and Drug Administration. There are reports that topiramate or tetrabenazine may also be helpful.
Atypical antipsychotics, including risperidone and aripiprazole, are sometimes beneficial, and may be preferred over the typical agents. When a typical antipsychotic is required, haloperidol is generally regarded as the drug of choice. It is started at a low daily dose (0.25 mg), which is gradually increased by 0.25 mg every 4 or 5 days until there is maximum benefit with a minimum of side effects or until side effects limit further increments. A total daily dose of 2 to 8 mg is usually optimal, but higher doses are sometimes necessary. Side effects include extrapyramidal movement disorders, sedation, dryness of the mouth, blurred vision, and gastrointestinal disturbances. Pimozide, another dopaminergic-receptor antagonist, may be helpful in patients who are either unresponsive to or cannot tolerate haloperidol. Treatment is started with 1 mg/d and the dose is increased by 1 mg every 5 days; most patients require 7 to 16 mg/d. Phenothiazines such as fluphenazine are sometimes helpful for the management of tics, as also occasionally are dopamine agonists.
Injection of botulinum toxin A at the site of the most problematic tics may be worthwhile.
Treatment of any associated attention deficit disorder may include the use of a clonidine patch, guanfacine, methylphenidate, dextroamphetamine, desipramine, or atomoxetine, whereas obsessive-compulsive disorder may require selective serotonin reuptake inhibitors or clomipramine.
Patients occasionally respond favorably to clonazepam or carbamazepine, but diazepam, barbiturates, phenytoin, and cholinergic agonists (eg, deanol) are usually not helpful.
Neurosurgical treatment, for example, by prefrontal leucotomy, anterior cingulotomy, or thalamotomy, has not been helpful, but bilateral deep brain stimulation of various target sites has reportedly been worthwhile in otherwise intractable cases.
N. Deep brain stimulation for Tourette syndrome. Neurosurg Clin N Am. 2014;25:117–135.
DL. Tourette syndrome. Handb Clin Neurol. 2013;116:631–642.
ACQUIRED HEPATOCEREBRAL DEGENERATION
Acquired hepatocerebral degeneration produces a neurologic disorder associated with extrapyramidal, cerebellar, and pyramidal signs as well as dementia. Extrapyramidal signs include rigidity, rest tremor, chorea, athetosis, and dystonia. This condition is discussed in Chapter 5, Dementia & Amnestic Disorders.
Restless legs syndrome is characterized by an unpleasant creeping discomfort that is perceived as arising deep within the legs and occasionally in the arms as well. Symptoms tend to occur when patients are relaxed, especially while lying down or sitting, and lead to a need to move about. They are often particularly troublesome at night and may delay the onset of sleep. A sleep disorder associated with periodic movements during sleep may also occur and can be documented by polysomnographic recording. The cause is unknown, although the disorder may have a genetic predisposition; several genetic loci have been associated with the syndrome. The disorder seems especially common among pregnant women and is not uncommon among uremic or diabetic patients with neuropathy. Most patients, however, have no obvious predisposing cause.
Symptoms sometimes resolve after correction of coexisting iron-deficiency anemia, and they may respond to treatment with drugs such as dopamine agonists, levodopa, gabapentin, pregabalin, or opiates. Benzodiazepines are also sometimes helpful.
Dopaminergic therapy is the treatment of choice but carries the risk of augmentation. The term augmentation refers to the earlier onset or greater intensity of symptoms, a reduced latency to symptom onset when at rest, and a briefer response to medication. Augmentation seems to occur especially in relation to levodopa therapy (carbidopa/levodopa 25/100 or 50/200 taken approximately 1 hour before bedtime), prompting many to use a dopamine agonist in place of levodopa when dopaminergic therapy is required. When augmentation occurs in patients receiving levodopa, the daily dose should be divided; alternatively, a dopamine agonist should be substituted (pramipexole 0.125-0.75 mg or ropinirole 0.25-4.0 mg once daily). When augmentation occurs with an agonist, the daily dose should be divided or the patient switched to another agonist or to other medications.
If opiates are required, those with long half-lives or low addictive potential are preferred. Oxycodone is often effective; the dose varies with the patient. Gabapentin can be used instead of opioids and is taken once or twice daily, typically in the evening and before sleep. It is started at 300 mg daily, and the dose is then built up depending on response and tolerance (to approximately 1,800 mg daily). Clinical studies suggest that pregabalin, 150 to 300 mg daily taken in divided doses, is also effective.
W. Restless legs syndrome and periodic leg movements in sleep. Handb Clin Neurol. 2011;99:913–948.